湖南中医杂志2025，Vol.41Issue(7)：41-48,8.DOI:10.16808/j.cnki.issn1003-7705.2025.07.008
基于真实世界分析中药联合化疗治疗晚期非小细胞肺癌的中医辨治用药规律及预后影响因素
Medication rule of syndrome differentiation-based traditional Chinese medicine treatment combined with chemotherapy in treatment of advanced non-small cell lung cancer and influencing factors for prognosis:An analysis based on the real world
摘要
Abstract
Objective:To investigate the syndrome differentiation and medication rules of traditional Chi-nese medicine(TCM)prescriptions in TCM combined with chemotherapy for the treatment of advanced non-small cell lung cancer(NSCLC),as well as the influencing factors for prognosis.Methods:Medical records were collected from the patients with advanced NSCLC who received chemotherapy combined with TCM treatment(integrated treatment group)or chemotherapy alone(chemotherapy group)from June 2018 to June 2023.The frequency of use of drugs,functions,and the cluster analysis were performed for the drugs in TCM prescriptions in the integrated treatment group,and general information and treatment regimens were recorded.Median progression-free survival(PFS)was calculated,and the influencing factors for prognosis were analyzed.Results:A total of 219 patients were enrolled,with 112 in the integrated treatment group and 107 in the chemotherapy group.The analysis of the TCM prescriptions for the patients in the integrated treatment group showed that commonly used drugs included tangerine peel and Poria cocos,with the most common function of tonifying deficiency.The cluster analysis obtained four drug combinations with the following functions:tonifying Qi and strengthening the spleen and stomach;regulating Qi,re-solving phlegm,and resolving static blood;nourishing Yin,clearing heat,and suppressing Yang;purging fire,drying dampness,and detoxicating.Comparison of median PFS showed that the integrated treatment group had a better re-sult than the chemotherapy group in overall treatment and the first-,second-,and third-line treatment,while the chemotherapy group had a better result than the integrated treatment group in the fourth-line treatment or above,and there was a significant difference between the overall treatment and the first-line treatment(P＜0.05).Stage and combination treatment were independent influencing factors for PFS(P＜0.05).Conclusion:The treatment of patients with advanced NSCLC based on syndrome differentiation can prolong the cycle of chemotherapy and delay disease progression.关键词
非小细胞肺癌/化疗/中药/预后疗效/用药规律Key words
non-small cell lung cancer/chemotherapy/traditional Chinese medicine/prognosis/medication rule分类
医药卫生引用本文复制引用
吴冠锦,周慧灵,叶轩婷,姚嘉麟,焦丽静,龚亚斌,陈智伟,许玲..基于真实世界分析中药联合化疗治疗晚期非小细胞肺癌的中医辨治用药规律及预后影响因素[J].湖南中医杂志,2025,41(7):41-48,8.基金项目
国家重点研发计划中医药现代化专项(2023YFC3503302) （2023YFC3503302）
国家自然科学基金项目(82274595) （82274595）
上海市科委科技创新行动计划医学创新研究专项(22Y31920400) （22Y31920400）
